利妥昔单抗在难治性肾病综合征患儿中的疗效及对肾损伤标志物表达的影响研究  

Study on Effect of Rituximab in Children with Refractory Nephrotic Syndrome and Its Influence on the Expression of Renal Injury Markers

作　　者：何晨明 HE Chenming(South Hospital of Fujian Provincial Hospital,Fuzhou 350001,China)

机构地区：[1]福建省立医院南院,福建福州350001

出　　处：《中外医学研究》2023年第18期14-17,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究利妥昔单抗在难治性肾病综合征患儿中的疗效及对肾损伤标志物表达的影响。方法:选取2018年6月—2021年9月福建省立医院南院收治的80例难治性肾病综合征患儿作为研究对象,根据随机数表法将其分为对照组40例和观察组40例。对照组进行常规治疗,观察组在对照组基础上加用利妥昔单抗治疗。比较两组治疗总有效率、不良反应发生率、复发率、治疗前后疾病相关指标[白蛋白(ALB)、总胆固醇(TC)及24 h尿蛋白(24 h UP)]及肾损伤标志物[中性粒细胞明胶酶相关载脂蛋白(NGAL)及视黄醇结合蛋白(RBP)]。结果:观察组治疗总有效率显著高于对照组,不良反应发生率显著低于对照组,治疗后6个月、9个月及12个月复发率显著低于对照组,差异有统计学意义(P<0.05)。治疗前,两组疾病相关指标及肾损伤标志物比较,差异无统计学意义(P>0.05);治疗2周、4周后,两组ALB显著高于治疗前,TC、24 h UP、NGAL、RBP显著低于治疗前,且观察组均优于对照组,差异有统计学意义(P<0.05)。结论:利妥昔单抗在难治性肾病综合征患儿中的疗效较好,安全性较高,且可有效控制肾损伤标志物。Objective:To investigate the effect of Rituximab in children with refractory nephrotic syndrome and its influence on the expression of renal injury markers.Method:A total of 80 children with refractory nephrotic syndrome who treated in South Hospital of Fujian Provincial Hospital from June 2018 to September 2021 were selected as the study objects,and they were divided into the control group of 40 cases and the observation group of 40 cases according to the random number table.The control group was treated with routine treatment,and the observation group was treated with Rituximab on the basis of the control group.Then the total effective rates,adverse reactions rates,recurrence rates,disease related indexes[albumin(ALB),total cholesterol(TC)and 24 h urinary protein quantity(24 h UP)]and renal injury markers[neutrophil gelatinase-associated lipocalin(NGAL)and retinol binding protein(RBP)]before and after treatment of two groups were compared.Result:The total effective rate of the observation group was significantly higher than that of the control group,the adverse reactions rate was significantly lower than that of the control group,the recurrence rates at 6 months,9 months and 12 months after treatment were significantly lower than those of the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in disease related indicators and renal injury markers between two groups(P>0.05);at 2 weeks and 4 weeks after treatment,the ALB of two groups were significantly higher than those before treatment,and the TC,24 h UP,NGAL and RBP were significantly lower than those before treatment,and those of the observation group were significantly better than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Rituximab in children with refractory nephrotic syndrome is better,and its safety is high,it can effectively control the expression renal injury markers.

关 键 词：利妥昔单抗 难治性肾病综合征 儿童 疗效 肾损伤标志物 

分 类 号：R726.9[医药卫生—儿科]